Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins
about
Systematic review of dasatinib in chronic myeloid leukemiaPharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaRole of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacologyStructural basis for the drug extrusion mechanism by a MATE multidrug transporterInhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitorsTransport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritisAlterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metforminMATE1 regulates cellular uptake and sensitivity to imatinib in CML patientsCommon drugs inhibit human organic cation transporter 1 (OCT1)-mediated neurotransmitter uptake.Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modelingNucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors.Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines.Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Metformin: multi-faceted protection against cancer.Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatmentContribution of tumoral and host solute carriers to clinical drug response.Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersA phosphotyrosine switch regulates organic cation transporters.Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects.Metformin pathways: pharmacokinetics and pharmacodynamicsSorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.Uptake carriers and oncology drug safety.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics.Transporter-mediated drug-drug interactions with oral antidiabetic drugs.Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters.A Comprehensive Review of Drug-Drug Interactions with Metformin.Role of organic cation transporters in drug-drug interaction.Genetic and/or non-genetic causes for inter-individual and inter-cellular variability in transporter protein expression: implications for understanding drug efficacy and toxicity.Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.Metformin and pancreatic cancer: Is there a role?Organic cation transporter 6 directly confers resistance to anticancer platinum drugs.Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine.Prediction and validation of enzyme and transporter off-targets for metformin.Expression of organic cation transporter 1 (OCT1): unique patterns of indirect regulation by nuclear receptors and hepatospecific gene regulation.The Role of Transporters in the Toxicity of Chemotherapeutic Drugs: Focus on Transporters for Organic Cations.Renal Drug Transporters and Drug Interactions.
P2860
Q24596026-FB12F16F-2417-497D-956F-9B210BD6C857Q26781539-A3771732-E915-458D-9C03-AA7B81816B08Q27026858-38CD40E2-03B9-41D3-938C-0229234FA6EEQ27684293-E1E0FABA-1268-4D2C-8E88-4D2FCAA8A78EQ28239708-81A80355-7960-4817-92A9-D3329957A13EQ28484465-FA41C096-AF02-42D1-81C6-1BA6BA7E1E3CQ28485299-38ABCCB0-CA77-49E1-9CCD-E45C29A711DBQ30313870-A10FD2D1-7228-4CC1-82DB-B5738D05FFD1Q33584577-DF6CCFF9-ECEC-44E9-855B-D10107A36001Q33799288-3C95D2C1-3CB0-432B-8534-CAB0D03E9BC6Q34025097-A3E2022A-CAAA-4C4B-A2BB-975DD2C2AAF3Q34651354-CBB25C72-5F8F-4164-AF32-4598AAA88FC4Q35675566-163C9A69-8D9A-4E60-B367-D03E3FDA0E52Q35708124-BF6BA163-1C7F-47C5-BBFF-91561DC1B57CQ35764409-79062709-2D59-45B1-9494-9B0C4B11848DQ35922779-1583E9C6-DBCC-405C-9D42-2251BBBD1637Q35946876-A820D28C-7E4D-44FF-BF10-097CCDBA5AD6Q36243653-BF6ABD32-03FB-47CB-BBEF-BFACD8795BE9Q36689589-7F2B93C6-0737-461D-A991-397294C96921Q36704820-67F54A1C-503A-4662-9F84-6E1389749219Q36737021-C9D46BE5-9629-499E-B874-CA694EA12F78Q36836472-A09D1402-1B74-4F60-8F13-11083F8B4DB9Q36852518-3F376F94-769E-4291-BF72-97969172BFAAQ37193103-2CAC5AAB-A4CF-4378-BF1C-D9EF7B363ACFQ37663396-EA646D34-A165-4135-ACA8-2F17242952E8Q37873453-7CB31BB0-20E1-47AF-9450-F452B5CF778CQ37933394-2299CB24-5944-4C1D-8F37-59755B1CC490Q38168993-4DA7421D-61E9-47A3-B773-190F1ED292C8Q38336723-B4C5ACC4-B9F3-48C4-98F3-77C861CF968CQ38460322-0E0596F3-9E25-4090-AEE7-206D430D52EBQ38553282-AB986492-1A70-4716-A374-1B0D131C059BQ38613161-D258395A-25F3-465D-B882-43BC388B62CFQ38622785-C685BF0D-91DB-440F-93DF-1BE956A7A5C5Q38689022-97A528A7-5819-40A3-888C-A2D06B4117FEQ38729178-290BB67C-5214-47F5-A30F-38F39B092F23Q38831370-1E527620-91CC-4415-A7C2-058FA0619A19Q38838317-981AD80E-C7CC-4481-87BF-10575F9240B7Q38859468-B05A030E-A4F7-4E8A-963C-E4BBD87D2ECCQ38888345-47AD065A-D369-445F-9005-4B44D7D2B509Q39140289-17796C74-A3FD-4C8C-8030-A9C6D6998F6F
P2860
Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Interactions of tyrosine kinas ...... ic compound extrusion proteins
@ast
Interactions of tyrosine kinas ...... ic compound extrusion proteins
@en
Interactions of tyrosine kinas ...... ic compound extrusion proteins
@nl
type
label
Interactions of tyrosine kinas ...... ic compound extrusion proteins
@ast
Interactions of tyrosine kinas ...... ic compound extrusion proteins
@en
Interactions of tyrosine kinas ...... ic compound extrusion proteins
@nl
prefLabel
Interactions of tyrosine kinas ...... ic compound extrusion proteins
@ast
Interactions of tyrosine kinas ...... ic compound extrusion proteins
@en
Interactions of tyrosine kinas ...... ic compound extrusion proteins
@nl
P2860
P1476
Interactions of tyrosine kinas ...... ic compound extrusion proteins
@en
P2093
Kathleen M Giacomini
Tsuyoshi Minematsu
P2860
P304
P356
10.1158/1535-7163.MCT-10-0731
P577
2011-01-20T00:00:00Z